walensky: and then, right on its heels will be the acip from the cdc to, sort of, give some guidanceshould be rolled out. reporter: can i just follow up a bit though? do you have any idea of how many doses there will be? the science is not guiding that. you know whether they are manufacturing and where they are in that. dr. fauci: yeah. >> yeah -- >> no, they have been contracted for 100 million doses, which we will hopefully get by the end of june, the beginning of july. the rollout of that -- there will not be a lot of doses right on the heels of eua, but that will accelerate as we get into the months towards the contractual arrangement of when 100 million doses will be given. mr. slavitt: yeah. and we will be speaking to that also. but again we are going to wait for the fda and the acip to do their work, and then i commit to you, you will be hearing a lot more, presuming that the eua is granted. and we are, -- and we are not, of course, going to take anything for granted, but presuming that that happens, i commit to you, youa™ll be -- you will be hearing a lot more about all those

i look forward to the acip discussion, receiving their recommendations and sharing with you about acip's recommendations and our next steps moving forward. thank you. i look forward to your questions and with that i'll turn things over to dr. fauci. >> thank you very much, dr. walensky. i'm going to give now a brief update on the science particularly focusing on the vaccine. if i go to the first slide. this is the slide that i've shown to this group before but building on what dr. walensky just said, we're looking forward with very positive anticipation to the final determination of the verpack and the fda concerning the johnson & johnson vaccine. what this means from data that we looked at, that we now have three highly effective vaccines. importantly, each of them are very effective against severe disease and virtually all of them say that he look at the data and it is clear that you get essentially no hospitalizations or deaths in any of them. this is very good news. so, again, we have three candidates now that are in play. we look forward to the results as dr. walensky said. this sho

i look forward to the acip discussion, receiving their recommendations and sharing with you about acip's recommendations and our next steps moving forward. thank you. i look forward to your questions. i will turn things over to dr. fauci. >> thank you very much, dr. walensky. i'm going to give now a brief update on the science, particularly focusing on the vaccine. if i can go to the first slide. this is the slide that i have shown to this group before. just building on what dr. walensky just said. we really are looking forward with very positive anticipation to the final determination of the fda concerning the johnson & johnson vaccine. what this means from the data we looked at that we now have three highly effective vaccines. importantly, each of them are very effective against severe disease and virtually all of them say you look at the data and it's clear that you get essentially no hospitalizations or deaths in any of them. this is very good news. again, we have three candidates now that are in play. we look forward to the results, as dr. walensky said. this should be forthcoming w

. >> following the fda's actions, the advisory committee on immunization practices, or acip, meets to in the advisory meeting. then acip will make recommendations for use of the vaccine and i will stand by ready to review them and sign. >> steve medical correspondent sanjay gupta is standing by to talk about this. sanjay, what are you expecting to see in the coming days? how fast will this new vaccine from johnson & johnson become available? >> it could happen very fast, brianna. we have some precedent on this because we saw this process play out with pfizer and moderna, you remember, and in those situations the advisory committee met and that evening or that day the fda actually approved that recommendation, so then you have an authorized vaccine. the cdc basically would meet to determine the who, how, when, meaning who is going to get this, how the vaccine is going to be rolled out, those sorts of recommendations, and then you just heard from dr. walensky who would give that final approval. there's a lot of steps but it can happen quickly. we also know johnson & johnson has been man

and it may be that acip wants to look at that and do some fine tuning.here was a little question in the discussion today whether we were absolutely sure that the j & j vaccine was just as good in the elderly as the other vaccines. and they may be looking at that, although the data looks very encouraging. >> you have warned, dr. collins, that these viral variants out there potentially could set back some of the recent progress. and you mentioned the numbers seem to be plateauing right now. some believe it's because of these variants. on the current path and now with the addition of the johnson & johnson vaccine, will we be able to vaccinate americans quickly enough to keep things under control? >> well, wolf, that's the big question. and the best answer to that is let's hurry up and go as fast as we can. there are these variants, one in the u.s. calleed b 117, which i getting more frequent every day. the problem with that variant is it's more contagious, which is all the more reason both to get the vaccines into arms but also for all of us to double down

b, the cdc's acip committee will ultimately give dpiedance on who should get the vaccine and when. or c, johnson & johnson's vaccine is mrna-based which uses a synthetic virus to enter the cells. >> hearing that people on facebook live are voting b and c. saying one of the answers. two truths and a lie. i'm stalling to give myself time to think. i have a feeling that b might be the one that is false. that's a lie. viewers also agree with me. leaning towards b as answer. part about acipacipacipacipacipp give guidance and when, but it's advised a strong efficacy rate in people 18 and older, that's the crutch i'm leaning on now, going with b. >> that's actually true but respect the analysis. a, really important, everyone understand this, there is enough early evidence to suggest that not only the johnson & johnson and moderna and pfizer will reduce symptomatic infections and also asymptomatic infections, prevent people from transmitting the virus, huge win. but b is true, now that the independent review board gave the green light to the fda, cdc's committee will look at data and give

guest: it is called acip. the advisory committee on immunization practices.erts are pediatricians, family physicians, people who have done vaccination trials in the past. a consumer representative on that committee. there are 15 voting members. some represent federal agencies. there are about 29 nonvoting representatives who are each representing an authorization that has an interest in vaccination. the american academy of pediatrics or the american colleges of obstetricians and gynecologists. they all attend the meeting and can contribute to the discussion, but they do not vote . this committee deals with vaccines after they have been approved for use. what this committee does is look at who should be vaccinated. in the case of the covid vaccine, they have been setting guidelines, federal guidelines, for who should come first in the program. health care workers should be first, followed by people 75 -- excuse me, health care workers and residents of nursing homes and people 75. those are the people who have been setting those kinds of priorities. host: robin

articulate that while it's not in our school guidance that it's a prerequisite for schools to open, our acip advisory committee on immunization guidance does put teachers in the 1b category for vaccination. that is vaccination of the same group as greater than 75-year-olds. so i'm a strong advocate of teachers receiving their vaccinations, but we don't believe it's a prerequisite for schools to reopen. >> what is your response to the cdc director and her agency's guidance? >> the vaccine is a lifesaving medical intervention. why wouldn't we want school workers, teachers and school clerks and lunch ladies to have access to that vaccine? i think that is more than reasonable, i think it's also humane. listen, it's never been about the guidelines per se in chicago, it has always been about the generations of neglect, underresourcing, underfunding and the defunding, quite frankly, of public education here. to ask individuals who have had had a very disparate experience with the chicago public schools to all of a sudden trust their ability to resource them and keep them safe in the middle of a pan

but we will know reasonably soon when the data become public and available and the acip weighs in on break and continue our questioning, but very quickly, what if you get two shots of the johnson & johnson, does it become more effective as a result of that? >> we don't know that, but it is likely that it will be. in fact, j & j is already into a study looking at what the effect of a single followed by a boost. we're going to know that information within a period of time. but you can imagine that if one dose gives you a certain amount that a boost will certainly make that better. >> that's encouraging to hear that. stay with us, dr. fauci. i know you have a lot going on. we have a bunch more questions that are critically important. we'll take a quick break, resume the conversation when we come back. university of phoenix is awarding up to one million dollars in new scholarships through this month, because hope fuels opportunity. see what scholarship you qualify for at phoenix.edu if you have postmenopausal osteoporosis and a high risk for fracture, now might not be the best time to as

. >> yes, acip put teachers in the 1b category, category of essential workers.be clear that there is increasing data that suggest that schools can safely re-open and that that safe re-opening does not suggest that teachers need to be vaccinated in order to re-open safely. >> i mean, practically everything about schools has been hotly debated, but jen psaki, the white house press secretary, was asked about this and how joe biden feels about that. she just said this afternoon, look, obviously, joe biden wants everybody, all teachers, to be able to be vaccinated. but given that this is a critical question, do you agree with that? do you think it's not necessarily necessary for teachers to get vaccinated before going back to in-person learning? >> i do endorse that statement for the following reasons. there are a number of independent schools who had adequate resources to put into place for mitigation strategies such as masking and distancing and they were able to successfully run their schools all fall before we had vaccines available. i believe that the biden admi

i'm waiting on acip and then there's a committee on immunization practices to set who to prioritize thenson & johnson vaccine for. there will be slightly different boundaries than will determine who gets the vaccine in the next six to nine months. next year it will be a different story as we create new boosters for a variant. >> i don't care what vaccine i get, just want a vaccine. i'll roll up my arm and take what i can get skwlirks back to the car accident involving this man, tiger woods. the fact that he's awake and alert this afternoon is really being called a miracle, but what will it take him to overcome such devastating injuries? we'll talk to a doctor. >>> voting rights across the country under attack. the latest on gop efforts to limit access to ballots. this is the epson ecotank color printer. no more buying cartridges. big ink tanks. lots of ink. print about this many pages. the new epson ecotank. just fill and chill. good morning, mr. sun. good morning, blair. [ chuckles ] whoo. i'm gonna grow big and strong. yes, you are. i'm gonna get this place all clean. i'll give you a

and i think that's also going to be part of the discussion that the -- what is called acip, this immunizationpractices commission of the cdc will be shedding light on. they are the ones who determine where the existing vaccines go. if there's 4 million, where exactly are they going to go? we haven't heard a lot about this. keep in mind with moderna and pfizer, we had a much better sort of sense of what was going to be happening at this point in the calendar of events. we haven't heard as much about the johnson & johnson vaccine yet. >> dr. sanjay gupta, this is happening realtime. a lot of data that you took a break. you lifted your head up to talk to us in the midst of reading through this. we'll let you get back to digging in the data because there's a lot of interesting stuff there. thanks for being with us. >>> we're also getting breaking news on what could be president biden's first cabinet nominee to fail on capitol hill. may soon be a former cabinet nominee. breaking details, next. this phone paired with 5g ultra wideband-- wow! (vo) the new samsung galaxy s21 is on verizon 5g ultra wi

and sometimes what will happen is the acip, the cdc will say, it seems to work better for one group than another. let's really recommend it for that group. but we need to drill down on the data. >> i was interested to read overnight, dr. offit, that the fda is working now to put a plan in place to deal with the new variants. basically, as these variants become more dominant, and maybe vaccines not as effective against them, the fda is trying to put a system in place to handle that. what exactly wdoes that mean? what would they do or change going forward? >> here's when a line gets crossed. a line gets crossed when you have people who have received two doses of the vaccine that nonetheless are hospitalized with disease caused by one of these variants. that's when you know that we need that second generation of vaccine. the question is, how are you going to work on that second generation of vaccine in terms of allowing it to be used, say, through eua. and i think the more likely model will be the influenza model. where the vaccine would have to be tested to make sure that it's safe in a fe

articulate that while it's not in our school guidance that it's a prerequisite for schools to open, our acipization practices guidance does put teachers in the vaccination. that is vaccination of the same group as greater than 75-year-olds. so i'm a strong advocate of teachers receiving their vaccinations, but we don't believe it's a prerequisite for schools to reopen. >> the cdc and you in this interview keep recommending six feet of distance between students. this is, of course, one of the barriers keeping some schools closed because classrooms aren't big enough, you know, teachers are already overwhelmed by the number of students in their clas classroom. over the summer, you suggested in a private email to the mayor of newton, massachusetts, that three feet of distance was, quote, quite safe if people are masked. so is six feet absolutely necessary, or can students be safe at closer distances? >> great question, and thanks for asking. over the summer, we were much less disease and our guidance is a bit more flexible in terms of the distancing if you are at low rates of transmission, those

studies now with children 12 and older, but because we don't have great evidence with children, the acipng body for the country on everything related to vaccines basically gave priority to adults and said until we get better evidence for the pfizer vaccine at 16 and older and for the moderna -- the moderna is 16 and older and pfizer is 18 and older. and i defer to dr. patel, who i know has a lot of knowledge. >> have i some knowledge, but i also get a lot of questions from anxious and worried parents, teens and kids about this as well. and, you know, dr. brown's on point with the fact that we didn't have the data to actually definitively say hey, if this was proven effective and safe and people above the age of 16, we can just give to it younger kids as well. you know, children against the misnomer are not just little adu adult, and adults are not just big children. our bodies react differently to different medications, vaccines being one of them. and we may totally find out that younger kids, kids in trials age 12 or even younger may require a different dose. our immune responses are al